Akorn third quarter consolidated revenue increases 69 percent to $36.
Generated $7.6 million in operating cash flow and ended quarter with $126.6 million in cash and cash equivalents. Filed five fresh internally created ANDAs with a combined annual market size of $170 million. Acquired one ophthalmic item the ongoing company intends to launch in 2012. Launched injectable Levofloxacin 25mg/mL single-make use of vials. Related StoriesNew UCLA research looks at primary care medical house in reducing childrens' repeat visits to hospitalsPatients offered animal-assisted therapy at UCLA HealthGlan Clwyd Medical center N Wales spend money on Esaote's G-Scan MRI device for weight-bearing scanningRaj Rai, Chief Executive Officer, commented, Our results reflect a solid demand for all items across our portfolio.Today at ESC Congress 2015 The results will be featured at a late-breaking session, an annual event of the European Society of Cardiology that includes cardiologists from around the world, with the purpose of reducing the responsibility of cardiovascular disease. In addition, the data was published simultaneously in the European Heart Journal. Absorb is a first-of-its-kind device that functions like a permanent, metallic stent by opening a blocked artery in the heart, restoring blood providing and flow relief from symptoms of CAD. Nevertheless, unlike a metallic stent, which restricts vessel motion and limits future treatment plans permanently, Absorb is made of a naturally dissolvable materials that leaves behind a restored vessel free from a long term implant, with the potential to flex, dilate and pulse in response to different demands on the center, centered on people's lifestyle and activities.2,3 ‘The benefits of the ABSORB Japan study continue to affirm that Absorb displays solid performance near-term and preserves the vessel for potential future procedures,’ stated Takeshi Kimura, M.D., Ph.D., director, Department of Cardiovascular Medicine, Kyoto University Medical center, Japan, and principal investigator of the ABSORB Japan research.